PATH-17. CORRELATION OF COMMERCIALLY-AVAILABLE QUANTITATIVE MGMT (O-6-METHYLGUANINE-DNA METHYLTRANSFERASE) METHYLATION SCORES AND OVERALL GBM PATIENT SURVIVAL

OBJECTIVE: Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer. One of the most robust clinically-obtained biomarkers available for GBM is MGMT promoter methylation, which predicts improved outcome to standard of care alkylating chemotherapy. MGMT promoter leads to g...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Dovek, Laura, Nguyen, Nhung, Ozer, Byram, Liau, Linda, Nghiemphu, Phioanh, Cloughesy, Timothy, Lai, Albert
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692826/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.708
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars